Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.creatorGaspar, L
dc.creatorMoraes, C
dc.creatorFreitas-Junior, L
dc.creatorFerrari, S
dc.creatorCostantino, L
dc.creatorCosti, M
dc.creatorCoron, R
dc.creatorSmith, T
dc.creatorSiqueira-Neto, J
dc.creatorMcKerrow, J
dc.creatorCordeiro-da-Silva, A
dc.description.abstractHuman American trypanosomiasis, commonly called Chagas disease, is one of the most neglected illnesses in the world and remains one of the most prevalent chronic infectious diseases of Latin America with thousands of new cases every year. The only treatments available have been introduced five decades ago. They have serious, undesirable side effects and disputed benefits in the chronic stage of the disease - a characteristic and debilitating cardiomyopathy and/or megavisceras. Several laboratories have therefore focused their efforts in finding better drugs. Although recent years have brought new clinical trials, these are few and lack diversity in terms of drug mechanism of action, thus resulting in a weak drug discovery pipeline. This fragility has been recently exposed by the failure of two candidates; posaconazole and E1224, to sterilely cure patients in phase 2 clinical trials. Such setbacks highlight the need for continuous, novel and high quality drug discovery and development efforts to discover better and safer treatments. In this article we will review past and current findings on drug discovery for Trypanosoma cruzi made by academic research groups, industry and other research organizations over the last half century. We also analyze the current research landscape that is now better placed than ever to deliver alternative treatments for Chagas disease in the near future.
dc.description.sponsorshipLuís Gaspar is thankful to FCT for funding (scholarship reference: SFRH/BD/81604/2011). The research leading to these results has received funding from the European Community’s Seventh Framework Programme under grant agreement No.602773 (Project KINDReD), No. 603240 (Project NMTrypI) and COST Action CM1307.
dc.publisherBentham Science Publishers
dc.relation.ispartofCurrent Medicinal Chemistry, vol.22(37), p. 4293-4312
dc.subject.meshAntiprotozoal Agents/therapeutic use
dc.subject.meshChagas Disease/drug therapy
dc.subject.meshDrug Discovery/trends
dc.subject.meshTrypanosoma cruzi/physiology
dc.titleCurrent and future chemotherapy for chagas disease
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
Gaspar2015.pdf827.41 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.